Accessibility Statement

Press Releases


Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years

February 7, 2025

Tags |  Product

More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Nearly 90% of patients who achieved endoscopic response at one year sustained it at two years Omvoh is the first IL-23p19 antagonist to demonstrate multi-year,




Lilly reports full Q4 2024 financial results and provides 2025 guidance

February 6, 2025

Tags |  Financial

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue (i) grew by 20% compared to Q4 2023. Pipeline progress included the approval of Zepbound in the U.S. for moderate-to-severe obstructive sleep apnea in adults with obesity and




Lilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcement

January 23, 2025

Tags |  Financial

INDIANAPOLIS , Jan. 23, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on Feb. 6, 2025 . Lilly will also conduct a conference call that day with the investment community and media to further detail the




FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease

January 15, 2025

Tags |  Product

In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic response at one year Among those who achieved clinical remission and endoscopic response at one year, nearly 90% of patients maintained clinical remission with




Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance

January 14, 2025

Tags |  Financial

2024  revenue is expected to be approximately $45.0 billion for the full year, $4.0 billion above the midpoint of first-time 2024 financial guidance Q4  2024 revenue is expected to be approximately $13.5 billion , approximately $400 million below the low end of recently issued financial guidance




Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program

January 13, 2025

Tags |  Corporate

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3K α inhibitor currently in a Phase 1/2 clinical trial STX-478 could potentially address 30-40% of people with hormone-positive breast cancer, building on Lilly's




Lilly to participate in J.P. Morgan Healthcare Conference

January 7, 2025

Tags |  Financial

INDIANAPOLIS , Jan. 7, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the 43rd Annual J.P. Morgan Healthcare Conference , Jan. 13-16, 2025. David A. Ricks, Lilly chair and CEO, will participate in a fireside chat on Tuesday, Jan. 14 at 5:15 p.m. Eastern time.




Lilly commends ITC ruling cracking down on the unlawful importation and sale of knock-off tirzepatide products that put Americans at risk

December 23, 2024

Tags |  Corporate

<p>Evidence of harmful knockoff tirzepatide escalates &nbsp; INDIANAPOLIS, December 23, 2024 – In a win for patients, the judge overseeing Lilly’s International Trade Commission case determined that U.S. Customs and Border Protection should prevent the illicit import of knock-off tirzepatide products.&nbsp; The</p>




FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity

December 20, 2024

Tags |  Product

&nbsp; Averaging up to 20% of weight loss, adults taking Zepbound had at least 25 fewer breathing interruptions each hour as they slept Up to 50% of adults taking Zepbound no longer had symptoms associated with OSA after one year INDIANAPOLIS , Dec. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:




Lilly's Kisunla™ (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease

December 17, 2024

Tags |  Product

China is the fourth major market where Kisunla has received approval&nbsp; Kisunla was first approved in&nbsp;the United States&nbsp;in&nbsp;July 2024, approved in&nbsp;Japan&nbsp;in&nbsp;September 2024 and then in Great Britain in October 2024 INDIANAPOLIS , Dec. 17, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today